Cardionovum to launch Prolimus Biograde drug-eluting coronary stent system

106

Cardionovum has announced that it expects to launch in Europe, in the fourth quarter of 2012, its Prolimus Biograde, a next-generation sirolimus-eluting coronary stent system, which is designed to optimise long-term patient results. 

The thin-stent strut design of Prolimus Biograde, just 71 microns, minimises stent-metal-volume, and thus foreign-body effects, while providing uniform stent coverage through its strut architecture. The stent architecture incorporates a diameter-depending 6-8-10 intermediate and closed-cell stent design intended to cover all vessel diameters with the same ratio. The goal of such design is to ensure a homogenous drug elution into the arterial tissue of the stented lesion segment.

Furthermore, this new technology is designed to protect allergic patients against emission of metal ions. Prolimus Biograde is coated with Titanium, which is highly biocompatible and functions as a barrier against “metal-ion-bleeding” that prevents any stent-associated hypersensitivity reaction.

“It is not only the drug on a stent that counts for the optimal patient treatment,” said Michael Orlowski,CEO of Cardionovum. “It also is critically important what remains in the patient’s artery for the patient’s lifetime, after drug elution has gone.”

The clinically anti-proliferative drug Rapamycin (Sirolimus) is coated onto Prolimus Biograde with the natural and biodegradable polylactide acid (PLA) polymer. Due to the controlled, six-weeks drug release, the long-term inhibition of re-endothelialisation is successfully eliminated.

The new Prolimus Biograde DES technology promotes early re-endothelialisation and rapid healing. Its pro-healing Titanium stent surface promises long-term patient safety. The entire composition of all technical elements is designed to allow for a reduction of oral antiplatelet therapy in favor of the patient´s quality of life after stenting.